Press Releases

Press Releases

Date Title  
Feb 01, 2018
Prothena to Report Fourth Quarter and Full Year 2017 Financial Results and Host Webcast Conference Call on February 14
DUBLIN, Ireland, Feb. 01, 2018 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, announced today that it will report its fourth quarter and full year
Jan 03, 2018
Prothena to Participate in the 36th Annual J.P. Morgan Healthcare Conference
DUBLIN, Ireland, Jan. 03, 2018 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel therapies in the neuroscience and orphan categories, today announced that members of its senior
Nov 22, 2017
Prothena to Participate in the Evercore ISI Biopharma Catalyst/Deep Dive Conference
DUBLIN, Ireland, Nov. 22, 2017 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel therapies in the neuroscience and orphan arenas, today announced that members of its senior
Nov 16, 2017
Prothena Highlights Breadth of Novel Pipeline at R&D Day
Clinical development programs advancing toward key milestones Dr. Morie Gertz of Mayo Clinic discusses clinical aspects of AL amyloidosis and the role of cardiac biomarker NT-proBNP Novel discovery pipeline in neuroscience and orphan disease areas; highlights include tau and ALECT2 R&D Day hosted
Nov 07, 2017
Prothena Reports Third Quarter 2017 Financial Results and Provides R&D Update
Net cash used in operating and investing activities was $18.3 million in the third quarter and $94.8 million for the first nine months of 2017; quarter-end cash and restricted cash position of $460.1 million, provides funding to advance diverse pipeline Presented new research at HFSA Annual
Nov 01, 2017
Prothena to Participate in the Credit Suisse 26th Annual Healthcare Conference
DUBLIN, Ireland, Nov. 01, 2017 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, today announced that members of its senior management team will
Oct 31, 2017
Prothena to Report Third Quarter 2017 Financial Results on November 7
DUBLIN, Ireland, Oct. 31, 2017 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, will announce financial results for the third quarter and first nine
Sep 28, 2017
Prothena Reports Results from Phase 1b Multiple Ascending Dose Study of PRX003 in Patients with Psoriasis
Data demonstrated consistent safety, tolerability and pharmacodynamic effects as previously reported from Phase 1a single ascending dose (SAD) study Observed clinical efficacy and reductions in markers of inflammation were insufficient to advance PRX003 into mid-stage clinical development DUBLIN,
Sep 18, 2017
Prothena Presents New Research Supporting Clinical Relevance of Cardiac Biomarker NT-proBNP in AL Amyloidosis
Preclinical Research Demonstrating a Direct Relationship Between Misfolded Light Chain Toxicity and NT-proBNP Production Clinical Outcomes Research Showing a Correlation between NT-proBNP Response and Health-related Quality of Life Data Presented at Heart Failure Society of America Annual Meeting
Aug 15, 2017
Prothena to Present New Research on Cardiac Biomarker NT-proBNP in AL Amyloidosis at HFSA Annual Meeting
Preclinical Research Demonstrating a Relationship Between Amyloid Light Chain Toxicity and NT-proBNP Production   Clinical Outcomes Research Showing a Correlation between NT-proBNP and Health-related Quality of Life DUBLIN, Ireland, Aug. 15, 2017 (GLOBE NEWSWIRE) -- Prothena Corporation plc